uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
Show others and affiliations
2004 (English)In: Br J Cancer, ISSN 0007-0920, Vol. 90, no 9, 1740-6 p.Article in journal (Refereed) Published
Abstract [en]

The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in anthracycline-pretreated metastatic breast cancer (MBC). This phase II study evaluates the efficacy and safety of a 21-day cycle of oral capecitabine (1000 mg m(-2) twice daily, days 1-14) plus i.v. paclitaxel (175 mg m(-2), day 1) in anthracycline-pretreated advanced/MBC. In all, 73 patients were enrolled at 13 Swedish and Spanish centres. The objective response rate was 52% (95% confidence interval (CI): 40-63%) in the intent-to-treat population, including complete responses in 11%. Disease was stabilised in a further 29%. The median time to disease progression (TTP) was 8.1 months and the median overall survival was 16.5 months. The combination was generally well tolerated with a predictable safety profile. The most common treatment-related nonhaematological adverse events were hand-foot syndrome (42%), alopecia (30%) and diarrhoea (26%). The only treatment-related Grade 3/4 adverse events occurring in >5% of patients were alopecia (22%) and hand-foot syndrome (11%). Grade 3/4 neutropenia and lymphocytopenia were reported in 12 and 14% of patients, respectively. Capecitabine plus paclitaxel is highly active with a favourable safety profile in anthracycline-pretreated MBC.

Place, publisher, year, edition, pages
2004. Vol. 90, no 9, 1740-6 p.
Keyword [en]
Adolescent, Adult, Aged, Anthracyclines/therapeutic use, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Breast Neoplasms/*drug therapy/mortality, Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives, Disease Progression, Female, Humans, Maximum Tolerated Dose, Middle Aged, Paclitaxel/administration & dosage/adverse effects, Survival Rate, Treatment Outcome
URN: urn:nbn:se:uu:diva-81295PubMedID: 15150624OAI: oai:DiVA.org:uu-81295DiVA: diva2:109210
Available from: 2006-08-10 Created: 2006-08-10 Last updated: 2011-01-12

Open Access in DiVA

No full text

Other links

By organisation
Department of Oncology, Radiology and Clinical ImmunologyCentrum för klinisk forskning, Gävleborg

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 127 hits
ReferencesLink to record
Permanent link

Direct link